Clinical Trial Update: Study Evaluating Mitoxantrone in Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mitoxantrone in secondary progressive multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Secondary Progressive Multiple Sclerosis | Phase 3 | Status: TERMINATED